Yelak Biru

𝗧𝗵𝗶𝘀 𝗶𝘀 𝗺𝘆 𝟮𝟱𝘁𝗵 𝗖𝗵𝗿𝗶𝘀𝘁𝗺𝗮𝘀 𝘀𝗶𝗻𝗰𝗲 𝗺𝘆 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀. 25 years living with an incurable #cancer, #myeloma 25 years #CancerSurvivor 1/

Exactly fifty years ago, Dr. Durie published the Durie-Salmon Staging System. A breakthrough that forever changed the course of myeloma care. His work gave us hope when there was little to be found. Patients, caregivers, and the entire myeloma community will forever be grateful to him and Susie for their dedication and legacy. acsjournals.onlinelibrary.wiley.com/doi/10.1002/10…

As one of the principal academic beneficiaries of Dr. Brian Durie’s mentorship, guidance, and kindness I am heartbroken to hear of his passing. His contributions to myeloma and oncology are without parallel. Charismatic, brilliant, dedicated, Dr. Durie has had a huge impact on generations of myeloma researchers worldwide. He founded the @IMFmyeloma and led it for over 30 years. He founded the International Myeloma Working Group (IMWG) and led it for over 20 years. He developed the Durie Salmon Staging System, which to this day remains as a true staging system. Helped countless patients. Educated, trained, guided countless doctors from around the world. I could go on and on. I pray for him and his family.

@rabonour1 What a legacy! You've given countless families the priceless gift of hope and, most importantly, time. Wishing you all the best and even greater impact in your new role.

After 30 years, today was my last day on the bone marrow transplant unit at Indiana University. I have had the privilege of working alongside some of the brightest, kindest and hardworking people during my tenure. Along with our patients, these doctors, nurses, pharmacists, medical Assistants and more, helped shape the doctor I am today. I am eternally grateful. ❤️

@HadidiSamer @UTSWMedCenter @utswcancer @UAMSMyeloma Congratulations

Excited to be joining the myeloma group at @UTSWMedCenter @utswcancer Grateful for an incredible 4 years with the amazing team at the Myeloma Center in Arkansas @UAMSMyeloma thank you for the mentorship, support, and lifelong friendships. Here's to new beginnings and continued collaborations! #mmsm

@bdermanmd @ASCO For those in the area at this day/time, you may be interested in this workshop aacr.org/professionals/…

You are not alone in wondering what are the implications of the FDA ODAC vote last year on MRD negativity (and CR) as a surrogate endpoint for clinical trials in myeloma. I try to piece it together in this approachable primer for @ASCO daily news! Link below 👇

@ctoddkennedy @JanakiramMurali @IMFmyeloma @jmikhaelmd 🙋‍♂️raising my hand as one of them!

@JanakiramMurali @IMFmyeloma @jmikhaelmd Thanks to the IMF and the expert speakers for an extremely educational and inspirational patient and family seminar. Dr.Janakiram-you clearly have an enthusiastic patient fan club-not surprising, because you are so awesome!

Cool fireside chat b/w Joe and Shaji @IMFmyeloma @jmikhaelmd

Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’ curetoday.com/view/why-new-p… via @cure_today For most patients myeloma has become a chronic disease. @MyelomaTeacher @NorthTxMSG @VincentRK @IMFsupport

We want to share this important toxicity profile of GPRC5D BisAb- Talquetamab. GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series #Bib1" target="_blank" rel="nofollow noopener">nature.com/articles/s4140… Full link- rdcu.be/eAazx

SWIFT-seq is a powerful option as it can measure the number of CTCs, characterize the genomic alterations of the tumor, estimate the tumor’s proliferative capacity and measure prognostically useful gene signatures in a single test and from a blood sample,” said Dr. @IrenemGhobrial #mmsm dana-farber.org/newsroom/news-…

The EAA173/DETER-SMM #ClinicalTrial is exploring new treatments for patients with high-risk #SmolderingMyeloma. Interested in learning more? Click here: bit.ly/eaa173detersmm cc: @nsc_natalie, @mtmdphd, @VincentRK, @NorthTxMSG

@Melodie_Pfizer @James85340992 Congratulations, Melodie.

We eloped!! Sharing the first photos from our magical day! Love wins ❤️

1/ Our call to action is out in @BloodAdvances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.

This is fantastic news for our CART patients For ide-cel and liso-cel Less driving restrictions : 2 weeks from 8 weeks Less time needed to be at tertiary care center away from home - 2 weeks from 4 weeks Hope we can expand this to other CAR Ts soon #mmsm #lymsm

@Patients1stAON @IMFjimMYELOMA @VincentRK @MyelomaTeacher @IMFsupport The 4th musketeer was Cindy @MyelomaTeacher... we couldn't keep her out :)

@IMFjimMYELOMA @NorthTxMSG @VincentRK @MyelomaTeacher @IMFsupport I miss Jack too

Two nice “memories from this day” (1)IMF Support Group Leaders retreat. (2)Three amigos when there really were three. Life evolves and races by. Make the most of every day God gives us. Help someone, encourage someone every day! @NorthTxMSG @VincentRK @MyelomaTeacher @IMFsupport

@kinatsofrim @JoshuaRichterMD @Someone68423357 @AJurczyszyn That's is similar to other toxicities - irreversible neuropathy, heart failure, parkinsonism, isolating infection, etc. The key to me is that there is awareness of the side effects, and it's a patient/family/doc shared decision.

@JoshuaRichterMD @Someone68423357 @AJurczyszyn $GSK KVA events at any grade occurred in 92% & 93% of pts in the trials, while grade 3-4 events happened in 77% & 78% of pts in the studies. G3 & G4 events = loss of eyesight, even if it’s reversible in the majority which it is, it’s not reversible in a sig. minority of pts.

2 negative odac votes for blenrep. I missed the discussion but this drug has a role in myeloma. Hoping the fda still approves it. #mmsm

The DREAMM studies have proven Belantamab effective and that the eye-related side effects can be mitigated. Eye related side effects are nothing to take lightly, but patients should have the right to decide for themselves what risks they are willing to take. #mmsm

The EAA173/DETER-SMM #ClinicalTrial is exploring new treatments for patients with high-risk #SmolderingMyeloma. Interested in learning more? Click here: bit.ly/eaa173detersmm cc: @nsc_natalie, @mtmdphd, @VincentRK, @NorthTxMSG

Valuable insight into why MM patients need BelaMaf as a treatment option.

Sobering ODAC today - much less faith in competence of practicing 🇺🇸 oncologists to dose-reduce belantamab mafodotin than I'd have expected. I, and many of my #MMsm pts, still have 🤞🏻 for full FDA approval. RW data will help us optimize bela-maf dosing, and pts need this drug!

@MyelomaTeacher @FDA I just had the benefit of going after you! And Thank you!

You say things much more eloquently than me-but I agree 1000% #mmsm @FDA #ODAC

@MyelomaTeacher @FDA I agree... I prefer to have One more option. One more change. One more Hope! And working with my myeloma specialists and attending clinicians to manage the toxicity.

“missed opportunity” - as a patient the “missed opportunity” would be the @FDA does NOT approve Belantamab - Let patients decide if they are willing to take the risk! You are putting patients at risk by not granting access. #mmsm